Updated Perspectives on the Management of Relapsed and Refractory Multiple Myeloma
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Oncology Research and Treatment 2021;44,12:682–689. https://doi.org/10.1159/000520364
- Ereignis
-
Veröffentlichung
- (wo)
-
Würzburg
- (wer)
-
Universität Würzburg
- (wann)
-
2021
- Urheber
-
Heimberg, Linda
Knop, Stefan
- DOI
-
10.1159/000520364
- URN
-
urn:nbn:de:bvb:20-opus-249773
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:46 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Heimberg, Linda
- Knop, Stefan
- Universität Würzburg
Entstanden
- 2021
Ähnliche Objekte (12)
Sorafenib in patients with refractory or recurrent multiple myeloma
Multiple myeloma
S188: Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab
Editorial: Molecular imaging in multiple myeloma: an update and future perspectives
Sorafenib in patients with refractory or recurrent multiple myeloma
Multiple myeloma
S188: Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab
Editorial: Molecular imaging in multiple myeloma: an update and future perspectives
Sorafenib in patients with refractory or recurrent multiple myeloma
Multiple myeloma
S188: Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results
Efficacy of dose-reduced Ienalidomide in patients with refractory or recurrent multiple myeloma
Functional analysis of oncogenic lesions in multiple myeloma with potential significance for refractory disease
A GRP78-directed monoclonal antibody recaptures response in refractory multiple myeloma with extramedullary involvement
Carfilzomib based treatment strategies in the management of relapsed/refractory multiple myeloma with extramedullary disease
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
From transplant to novel cellular therapies in multiple myeloma : : european myeloma network guidelines and future perspectives
Retrospective study on pomalidomide-PACE as a salvage regimen in aggressive relapsed and refractory multiple myeloma
S183: Novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results for talquetamab (A GPRC5D X CD3 bispecific antibody) in combination with daratumumab